Tumor News and Research

RSS

Machine Learning Tool Uncovers Epigenome Patterns Without Predefined Labels

In a study recently published in Nature Communications, researchers from Berlin, Potsdam, and Jena present a new method for analyzing the epigenome, the genome's control system that determines which genes are switched on and off.

28 Aug 2026

OIST Scientists Uncover Fleeting Sugar Pairs Regulating Cell Division

Acting as an armor, a scaffold, and a communication platform in one, our cells' plasma membrane lies at the heart of many crucial cellular processes.

28 Aug 2026

Newly Found Fibroblasts Help Lung Tumors Evade Immune System

Researchers at Columbia University have discovered a new type of cell that protects lung cancers from attacks by the immune system.

28 Aug 2026

Colorectal Cancer and Nerve Damage: A Hidden Link Uncovered in Mice and Primates

Colorectal tumors trigger inflammatory nerve damage, suggesting cancer itself may be a risk factor for neuropathy in survivors, independent of treatments.

27 Aug 2026

Mutation Stalls Immature Brain Cell Maturation Leading to Aggressive Gliomas

Scientists at St. Jude Children's Research Hospital have shown that specific brain cells respond differently to the H3.3 K27M, a mutation in the histone H3.3 protein that drives many cases of diffuse midline glioma (DMG), depending on the cell's location in the developing brain.

27 Aug 2026

Engineering Stem-Cell-Derived Immune Cells to Teach T Cells to Fight Cancer

The human body contains vast numbers of T cells capable of seeking out and eliminating malignancies if they were properly activated. Currently, a group from UC San Francisco has developed a technique to achieve this by merging laboratory-cultivated immune cells with samples from a person's malignancy.

26 Aug 2026

Novel T-Cell Engineering Strategy Prevents Deadly Osteosarcoma Lung Metastasis

Scientists at St. Jude Children's Research Hospital have discovered that removing the gene for Regnase-1 from engineered immune cells makes them more effective at treating relapsed osteosarcoma.

26 Aug 2026

New Study Identifies FAM120A as Critical Protein in Tumor Establishment

Researchers investigating the role of progranulin in cancer progression have previously identified the signaling receptor EphA2 as critical in tumor establishment and potential target to enhance the effectiveness of chemotherapy.

26 Aug 2026

Study Redefines How Cancer Cells Enter Senescence

Stopping tumor growth is only half the battle. Rather than kill tumor cells, many cancer therapies can only push them into cellular senescence, a state in which cells stop dividing but do not die. These "undead" cells will continue to release signals that reshape the tumor environment.

21 Aug 2026

Antibodies for Visualizing Cell Identity and Tumor Architecture

Whether you are characterizing cell state transitions, assessing organelle integrity, or building a multiplex immunofluorescence (IF) assay, you need reliable structural markers for your imaging.

From Antibodies Incorporated 21 Aug 2026

Reengineering Glial Cell Signaling Pathways to Slow Down ALS Symptoms

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that, according to the CDC, currently impacts around 35,000 Americans-with 5,000 more diagnosed each year.

21 Aug 2026

Locally Activated Skull T Cells Halt Glioblastoma Growth in Mice

Researchers at Washington University School of Medicine in St. Louis have discovered lymph node-like structures in the skull bone marrow of mice for the first time and demonstrated that they act as rapid first responders against brain cancer before distant lymph nodes get the signal that abnormal cells are present.

20 Aug 2026

Researchers Reveal Overlooked Colorectal Cancer DNA Repair Breakdown Fingerprint

Researchers from University of California San Diego and collaborators have identified a previously overlooked pattern of DNA mutations in colorectal cancer.

20 Aug 2026

New Research Links Chronic Inflammation to Tumor Microenvironment Epigenetic Changes

Immune checkpoint inhibitors have revolutionized cancer treatment, yet many colorectal tumors remain resistant. Even among patients who initially respond, more than half eventually develop resistance, highlighting the need to better understand how tumors evade immune attack.

19 Aug 2026

New Potential Target for Triple-Negative Breast Cancer

The study uncovers how macrophages recruit nerves in triple-negative breast cancer, suggesting BDNF signaling as a critical factor in tumor progression.

18 Aug 2026

New Lipid Vesicles Evade Immune Cells to Target Cancer Tumors

Red blood cells serve as the foundation for nanocarriers that show promise in a new study as effective and efficient vehicles for gene therapy, tumor targeting and other medical treatments.

18 Aug 2026

New Proximity Labeling Method Discovers Critical Protein Interactions in Cancer

Using a photochemically driven labeling technique, a Cornell University-led research group has devised a strategy for capturing cancer-specific protein-to-protein interactions, which could one day spawn targeted therapies for prostate, small-cell lung, pancreatic and other deadly forms of the disease.

14 Aug 2026

Bacterial Membrane Particles Emerge As Promising Tools in Oncology Research

Bacteria shed membrane-enclosed tiny particles filled with proteins, lipids, DNA, RNA and metabolites. These particles, commonly known as bacterial extracellular vesicles (BEVs), are now being explored as possible tools for cancer diagnosis and treatment.

14 Aug 2026

Genomic Database Analysis Identifies New Target for Triple-Negative Breast Tumors

Triple-negative breast cancer accounts for approximately 15% of all breast cancer cases. It is characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression, rendering it insensitive to conventional endocrine and targeted therapies.

13 Aug 2026

New Oral Nanomedicine Leverages Gut Metabolites to Destroy Tumors

A joint research team-led by Professor Young Seok Cho from the School of Medicine, alongside Professor James J. Moon from the University of Michigan-has successfully developed the world's first oral, microbiome-based nanomedicine.

12 Aug 2026